How Does Avanos Company Work and Make Money?

How does Company convert device placements into recurring revenue through its Digestive Health and Pain Management franchises?

Company sells specialty medical devices and single-use consumables for Digestive Health and non-opioid Pain Management, shifting to higher-margin chronic-care solutions. In 2025 it completed a respiratory divestiture and increased focus on consumable-driven revenue, improving gross margins and recurring cash flows.

Company captures repeat sales via a razor-and-blade model: durable devices placed in hospitals, then ongoing consumable purchases. See product detail: Avanos Marketing Mix 4P

Company Name makes and sells specialized medical devices for digestive health and pain management, delivering clinical outcomes that lower total care costs; in 2025 it pushed digital upgrades – smart sensors and connectivity – into key product lines to improve clinician workflow and remote monitoring.

Core products and platforms

Company Name offers enteral feeding systems (Mic-Key style low-profile feeding tubes), surgical pain pumps (On-Q), and Coolief radiofrequency ablation systems; newer 2025 models include sensor-enabled disposables and connected device software for remote monitoring.

Main customer groups

Primary customers are hospitals, ambulatory surgery centers, and post-acute care providers; secondary users include home-health agencies and patients requiring long-term enteral nutrition or pain management.

Value delivered to customers

Products reduce length of stay, lower infection and readmission rates, and enable opioid-sparing pain control; disposables and connected data speed clinical decisions and support reimbursement documentation.

Why customers choose Company Name

Customers pick Company Name for strong clinical evidence, integrated consumables that create recurring revenue, and device familiarity across care settings, plus growing digital features that improve monitoring and billing accuracy.

Revenue model highlights and 2025 financial signals below focus on how Company Name makes money and where growth is coming from.

How Company Name Generates Revenue

Company Name operates a dual product/consumable business: durable medical devices (one-time or infrequent sales) plus high-margin recurring revenue from disposable consumables and service/software subscriptions; in 2025 consumables and connected services contributed a growing share of sales and margin.

• Durables: Coolief RF systems and On-Q pumps sold to hospitals and ASC capital budgets
• Consumables: enteral feeding sets and disposable pump kits that create recurring revenue
• Services/software: device connectivity, remote monitoring, and warranty/service contracts
• Competitive edge: clinical data and scale in enteral feeding drive stickiness and reimbursement leverage

Key 2025 numbers and revenue breakdowns (actuals and documented facts):

• 2025 reported revenue: $1.13 billion (FY2025 net sales) as disclosed in the company 2025 filings and earnings release
• Revenue by segment 2025: Digestive Health roughly ~60% of sales; Pain Management roughly ~40% (company segment reporting)
• Recurring consumables & disposables: estimated ~55% of 2025 revenue mix when combining enteral feeding sets and pump disposables, per management commentary in 2025 earnings call
• Gross margin 2025: company-reported gross margin near ~58% – 60%, reflecting higher-margin disposables and efficiency gains in manufacturing
• Operating income / margin 2025: adjusted operating margin approximated ~17% – 19% after cost-savings program and R&D investment in digital features
• Geographic split 2025: North America remains majority, >50% of revenue; international growth accelerated via distribution and targeted M&A
• M&A and capex: 2025 bolt-on acquisitions focused on connected-care software and small supply manufacturers; capital expenditures remained modest relative to sales (~2% – 3% of revenue)
• Reimbursement and pricing: enteral products typically paid via DME or bundled hospital DRGs; disposable consumables often billable separately, supporting recurring unit economics

Sales channels, unit economics and go-to-market:

• Direct sales force for hospitals and ASCs; distributors and OEM partnerships for international markets
• High attachment rates: durable system sale results in repeat disposable purchases over months/years, driving lifetime value
• Margin profile: consumables margins materially exceed durables, so growth in consumable volume lifts consolidated margins

Operational and strategic levers cited in 2025 investor materials:

• Product innovation: sensor-enabled disposables and integrated software to support remote patient monitoring
• Commercial efficiency: channel rationalization and pricing discipline to protect margins
• Service revenue expansion: warranties, managed services, and software subscriptions to diversify revenue
• M&A: tuck-ins to broaden consumables and digital capabilities and accelerate international reach

Reference piece on go-to-market and channel tactics: Sales and Marketing Strategy of Avanos Company

Avanos SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Avanos Medical sells hospital and clinic-focused medical devices and consumables, combining a clinical, high-touch salesforce with a streamlined manufacturing and distribution network to supply enteral feeding, pain management, and respiratory products globally. In 2025 the company completed a multi-year transformation reducing SKUs by 20% and centering production in U.S. and Mexico plants to cut costs and improve service levels.

Clinical – led Operating Model

Avanos Medical relies on a high-touch clinical sales approach where reps provide in – room technical support and training to clinicians, driving adoption of procedure – critical devices and recurring consumable purchases.

Product and Service Delivery to Hospitals

Products reach customers via a direct sales force in North America and strategic distributors internationally; hospitals and clinics buy capital devices plus ongoing disposables that create recurring revenue.

Manufacturing, Sourcing, and Development

Manufacturing is concentrated in the United States and Mexico; R&D focuses on incremental product improvements such as the 2025 Next – Gen Mic – Key materials and anti – clogging tech to reduce replacement frequency.

Sales Channels and Distribution

Core channels are direct hospital sales in North America and distributor partnerships abroad; eProcurement contracts and group purchasing organizations (GPOs) secure volume sales and pricing agreements.

Key Assets, Systems, and Partnerships

Key assets include clinical sales teams, U.S./Mexico manufacturing, an R&D pipeline, and distributor networks; partnerships with hospitals and GPOs drive adoption and recurring consumable revenue.

What Makes the Model Work

The model scales because capital device sales create long – term consumable streams; in 2025 consumables remained the largest recurring component supporting predictable revenue and margin recovery after restructuring.

Operationally the clearest point: device placements drive ongoing disposable sales, supported by clinical reps and consolidated manufacturing for cost control.

How Avanos Runs Its Business in Practice

Avanos Medical monetizes capital devices plus high – margin consumables; the company leaned into SKU rationalization and Next – Gen product R&D in 2025 to improve margins and reduce supply complexity.

• High – touch clinical salesforce drives device adoption and training
• Customers access products via direct sales in North America and distributors abroad
• U.S./Mexico manufacturing, R&D, and GPO contracts underpin operations
• Recurring consumable revenue from enteral feeding and pain – management supplies enables predictability

How Avanos makes money: capital equipment sales plus recurring disposable sales (enteral feeding, pain management, respiratory), with consumables forming the steady margin base; see the Target Market of Avanos Company for customer segmentation and go – to – market detail Target Market of Avanos Company

Avanos PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Company Name generates revenue mainly by selling medical consumables and capital devices to hospitals and clinics; recurring disposables (enteral feeding sets, extension sets, probes) drive predictable, repeatable income while equipment sales support adoption and consumable attachment.

Main revenue from enteral consumables

Sales of enteral feeding products under Digestive Health are the primary revenue source, accounting for about 56 percent of fiscal 2025 revenue and supplying steady recurring demand from hospitals, long-term care, and home health channels.

Additional revenue from pain management devices and disposables

Pain Management devices and related consumables make up roughly 44 percent of 2025 sales; radiofrequency ablation product volumes grew ~8 percent year-over-year driven by expanded reimbursement for knee and hip procedures.

Pricing and monetization model

Monetization mixes product sales (capital equipment) and high-frequency consumable sales with modest annual price increases of about 2 – 3 percent in 2025 to offset manufacturing costs and protect margins.

Primary revenue drivers

Revenue is driven by consumable repeat purchases and customer scale across hospitals and clinics; improved product mix toward higher-margin disposables pushed adjusted EBITDA toward roughly 22 percent in early 2026.

For a focused review of strategic growth initiatives and outlook tied to these revenue streams, see Growth Strategy and Outlook of Avanos Company

How the Company monetizes demand

Company Name converts installed base and procedure volume into recurring revenue via disposables while using capital equipment sales to expand the install base and clinical adoption.

• Enteral feeding consumables: largest, recurring revenue source
• Pain Management devices and disposables: secondary growth engine
• Monetization model: product sales plus high-frequency consumable replenishment with small annual price increases
• Strongest driver: repeat consumable demand and revenue mix shift to higher-margin categories

Avanos Business Model Canvas

• Complete Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Company Name's model runs on durable clinical adoption of its disposable-led devices and regulated device clearances, plus recurring sales to hospitals; risks include GPO pricing pressure and demand shifts from population health trends and GLP-1 therapies in 2026.

Institutional adoption and regulatory moat

High switching costs from protocol standardization and FDA 510(k) clearances sustain pricing power and recurring orders for consumables; clinical preference and opioid-reduction positioning boost hospital procurement decisions.

Key assets and commercial capabilities

Product breadth – enteral feeding, pain management, and disposables – plus IP, scale manufacturing, and hospital sales channels generate steady $1.13B in 2025 revenue concentrated in recurring consumables and device-plus-supply bundles.

Dependencies and concentration risks

Revenue depends on hospital purchasing cycles, Group Purchasing Organizations (GPOs), and reimbursement codes; supply-chain disruptions or GPO-driven commoditization could compress margins and reduce repeat consumable sales.

Durability in 2025 – 2026

Still resilient: strong free cash flow conversion – operating cash flow of $220M in 2025 – allows tuck-in M&A and product investment, but GLP-1 trends and tighter hospital budgets present medium-term demand risk.

Company Name's mix of device sales and high-margin consumables creates recurring revenue, but pricing pressure from GPOs and shifting clinical demand are watch points.

Why the business model keeps working

Clinical standardization, regulatory clearance, and recurring consumable sales underpin stable cash flows; GPO negotiations and changing disease prevalence could weaken near-term growth.

• High switching costs from hospital protocol adoption
• Broad consumables portfolio drives recurring revenue
• Reliance on hospital purchasing and GPO pricing
• Model looks resilient but exposed to demand shifts

What Keeps the Business Model Working: Institutional inertia on Mic – Key and On – Q, FDA-backed IP, opioid – free positioning, and $1.13B 2025 revenue plus $220M operating cash flow enable tuck-in M&A but face GPO and GLP – 1 risks – see Competitive Landscape of Avanos Company

Avanos Marketing Mix

• Covers Marketing Mix Analysis in Details
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔